Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: For patients with metastatic prostate cancer, treatment is primarily palliative, relying mainly on the suppression of systemic androgen hormone levels. To help document the achievement of palliation and to characterize positive and negative effects of treatment, we evaluated quality-of-life (QOL) parameters in patients with metastatic prostate cancer who were randomly assigned to two methods of androgen deprivation. METHODS: Patients (n = 739) with stage M1 (bone or soft tissue metastasis) prostate cancer were enrolled in a QOL protocol that was a companion to Southwest Oncology Group INT-0105, a randomized double-blind trial comparing treatment with bilateral orchiectomy (surgical castration) plus either flutamide or placebo. Patients completed a comprehensive battery of QOL questionnaires at random assignment to treatment and at 1, 3, and 6 months later. Data were collected on three treatment-specific symptoms (diarrhea, gas pain, and body image), on physical functioning, and on emotional functioning. All P values are two-sided. RESULTS: Questionnaire return rates for this study never dropped below 80%; only 2% of the patients did not submit baseline QOL assessments. Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = .001) and worse emotional functioning at 3 and 6 months (both P<.003). Longitudinal analyses replicated these findings. Other analyzed QOL parameters favored the group receiving placebo but were not statistically significant after adjustment for multiple testing. CONCLUSIONS: We found a consistent pattern of better QOL outcomes at each follow-up assessment during the first 6 months of treatment for orchiectomized patients with metastatic prostate cancer who received placebo versus flutamide. Improvement over time was evident in both treatment groups but more so for patients receiving placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
McHorney, C. A., Ware, J. E., Rachel Lu, J. F., & Sherbourne, C. D. (1994) · Medical Care · doi:10.1097/00005650-199401000-00004 · Cited by 4,458
The MOS Short-form General Health Survey: Reliability and Validity in a Patient Population
Stewart, A. L., Hays, R. D., & Ware, J. E. (1988) · Medical Care · doi:10.1097/00005650-198807000-00007 · Cited by 3,339
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Self-citationQuality-of-life outcomes in men treated for localized prostate cancer
Litwin, M. S., Hays, R. D., Fink, A., Ganz, P. A., Leake, B., Leach, G. E., & Brook, R. H. (1995) · JAMA · doi:10.1001/jama.1995.03520260051032 · Cited by 1,020
Esper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00459-7 · Cited by 696
Prevalence of symptoms among patients with advanced cancer: An international collaborative study
Vainio, A., & Auvinen, A. (1996) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(96)00042-5 · Cited by 455
Cited by
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
Hussain, M., Tangen, C. M., Berry, D. L., Higano, C. S., Crawford, E. D., Liu, G., Wilding, G., Prescott, S., Kanaga Sundaram, S., Small, E. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212299 · Cited by 580
Self-citationProstate cancer and health‐related quality of life: a review of the literature
Eton, D. T., & Lepore, S. J. (2002) · Psycho-Oncology · doi:10.1002/pon.572 · Cited by 346
Dominick, K. L., Ahern, F. M., Gold, C. H., & Heller, D. A. (2002) · Aging Clinical and Experimental Research · doi:10.1007/bf03327351 · Cited by 275
A Quantitative Promoter Methylation Profile of Prostate Cancer
Jerónimo, C., Henrique, R., Hoque, M. O., Mambo, E., Ribeiro, F. R., Varzim, G., Oliveira, J., Teixeira, M. R., Lopes, C., & Sidransky, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0894 · Cited by 260
Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J., & Aronson, N. (2002) · Cancer · doi:10.1002/cncr.10647 · Cited by 259
Metadata
- Authors
- Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A., Eisenberger, M., Veith, R. W., Higgins, B., Skeel, R., Crawford, E. D., & Meyskens, F. L.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-10-21
- Volume
- 90
- Issue
- 20
- Pages
- 1537-1544
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2115744963
- Cited by
- 148
- References
- 7
- FWCI
- 11.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. https://app.cochat.ai/papers/10.1093/jnci/90.20.1537
- The paper
- Moinpour, C. M., Lovato, L. C., Yee, M., Blumenstein, B. A., Savage, M. J., Troxel, A., Eisenberger, M., Veith, R. W., Higgins, B., Skeel, R., Crawford, E. D., & Meyskens, F. L. (1998). Quality of Life in Advanced Prostate Cancer: Results of a Randomized Therapeutic Trial. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/90.20.1537
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.